检索问题
乳腺癌的治愈概率
乳腺癌（Breast Cancer）在全球范围内是最常见的癌症之一，也是女性癌症相关死亡的主要原因之一。了解乳腺癌的治愈概率需要综合考虑多个因素，包括癌症的分期、类型、基因特征，以及患者的整体健康状态等。因此，以下将详细探讨这些影响因素及其对乳腺癌治愈概率的影响。
乳腺癌的预后因素
-
癌症分期（Stage of Cancer）
乳腺癌的分期是影响治愈概率的一个重要因素。在早期（如I期和II期）发现并治疗的乳腺癌患者通常具有较高的治愈率。根据统计数据，I期乳腺癌的五年生存率一般可达98%以上，而II期的五年生存率在80-90%之间。相对而言，III期的五年生存率显著下降，大约在60%左右，IV期也就是晚期的生存率则低于30%。 -
肿瘤类型和生物特征
乳腺癌是一种异质性很强的癌症，其不同类型（例如浸润性导管癌、浸润性小叶癌、非浸润性癌等）和生物标记物特征（如ER、PR、HER2）会对预后产生显著影响。例如，“三阴性”乳腺癌（ER、PR、HER2均为阴性）通常预后较差，因为它们对传统的内分泌疗法和靶向疗法反应不佳。相反，HER2阳性乳腺癌因现代靶向治疗的进步，治愈概率有所提高。 -
治疗方法
随着医学技术的发展，乳腺癌的治疗手段不断丰富，包括手术、放疗、化疗、以及现代的靶向治疗和免疫治疗等。根据研究，结合治疗手段对提高治愈率至关重要。近年来的数据显示，一些新兴的治疗方法，比如冷冻消融（Cryoablation），为早期乳腺癌患者提供了一种有效的选择，且在维持乳房美观的同时，能够得到与传统治疗相似的肿瘤学结果。 -
基因和分子特征
科学研究表明，分子生物学的变化（如基因突变）能够影响治疗效果。例如，TP53、PIK3CA和PTEN基因的突变在某些乳腺癌患者中较为常见，且其可能影响患者对治疗的反应。此外，利用分子基因型分析可以更好地预测患者对特定治疗的反应，从而提高个体化治疗的成功率。
心理健康和支持因素
-
心理健康
乳腺癌患者常常伴随焦虑和抑郁等心理健康问题，这些问题会影响治疗的有效性和患者的生存质量。研究表明，积极的心理支持、心理治疗和药物治疗都有助于改善乳腺癌患者的心理状态，从而积极影响其生存率和恢复。 -
社会支持和治疗参与
患者的社会支持与参与临床试验也会对治愈概率产生积极作用。参与高质量的临床试验不仅能获得最新的治疗方法，还有助于改善治疗效果。
统计数据与展望
根据相关统计数据，乳腺癌的总体五年生存率在70%到90%之间，具体取决于上述因素的组合。诸如早期检测和个体化治疗的进展显著提高了整体治愈率。同时，针对特定基因组特征的靶向治疗和免疫治疗的发展为一些难治性乳腺癌患者提供了新的希望。
总结
综上所述，乳腺癌的治愈概率受多个因素影响，包括癌症的分期、类型、基因特征、以及患者的心理健康和社会支持。在现代医学技术进步的背景下，早期诊断和个体化治疗正在逐步提高乳腺癌患者的治愈率。尽管存在挑战，但通过结合最新的治疗策略和心理支持，乳腺癌的治愈前景仍然乐观。为确保最佳的治疗结果，患者应与医疗团队密切合作，探索适合自我的治疗方案。
References
1Biomarkers in Breast Cancer: An Old Story with a New End.PubMed
Lyvia Neves Rebello Alves, Débora Dummer Meira, Luiza Poppe Merigueti, et al.
Genes (Basel). 2023 Jun 28;14(7):1364. doi: 10.3390/genes14071364.
Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease and the leading cause of cancer mortality in women. Advances in molecular technologies allowed for the identification of new and more specifics biomarkers for breast cancer diagnosis, prognosis, and risk prediction, enabling personalized treatments, improving therapy, and preventing overtreatment, undertreatment, and incorrect treatment. Several breast cancer biomarkers have been identified and, along with traditional biomarkers, they can assist physicians throughout treatment plan and increase therapy success. Despite the need of more data to improve specificity and determine the real clinical utility of some biomarkers, others are already established and can be used as a guide to make treatment decisions. In this review, we summarize the available traditional, novel, and potential biomarkers while also including gene expression profiles, breast cancer single-cell and polyploid giant cancer cells. We hope to help physicians understand tumor specific characteristics and support decision-making in patient-personalized clinical management, consequently improving treatment outcome.
2Breast reconstruction.PubMed
Justin H Piasecki, Karol A Gutowski
Clin Obstet Gynecol. 2006 Jun;49(2):401-13. doi: 10.1097/01.grf.0000211913.24789.4b.
With over 200,000 new cases of invasive breast cancer treated each year, various types of breast reconstruction have become popular and safe. Immediate breast reconstruction seems to confer both benefit and patient satisfaction. A variety of techniques including subcutaneous expanders/implants, flap transfers, and free tissue transfers are described.
3Breast intervention and breast cancer treatment options.PubMed
Olive Peart
Radiol Technol. 2015 May-Jun;86(5):535M-558M; quiz 559-62.
Breast cancer is the second leading cause of death among women in the United States. Although controversy has emerged in recent years regarding the diagnosis and treatment of this disease, it remains important to detect and treat breast cancer before it has metastasized. This article provides an overview of breast biopsy techniques, biopsy specimen imaging, and treatment options for breast cancer patients, including surgery, radiation therapy, chemotherapy, and molecular treatments. Finally, breast reconstruction options are presented.
4Therapeutic landscape of metaplastic breast cancer.PubMed
N Tray, J Taff, S Adams
Cancer Treat Rev. 2019 Sep;79:101888. doi: 10.1016/j.ctrv.2019.08.004. Epub 2019 Aug 13.
Metaplastic breast carcinomas (MPBC) are rare, aggressive and relatively chemorefractory tumors with a high unmet need. While most are "triple negative" and lack expression of estrogen, progesterone and HER2 receptors, MPBC are associated with worse outcomes compared to conventional triple negative invasive tumors. MPBCs are genetically heterogeneous and harbor somatic mutations, most frequently in TP53, PIK3CA and PTEN, with emerging studies suggesting a role for novel targeted therapies. These tumors have also been associated with overexpression of PD-L1 and tumor-infiltrating lymphocytes suggesting an endogenous immune response and therefore a rationale for treatment with immunotherapies. Here, we focus on therapeutic options for this difficult to treat breast cancer subtype and encourage physicians to consider targeted therapies/immunotherapies as part of ongoing clinical trials.
5Coenzyme Q10 in breast cancer care.PubMed
Ali Tafazoli
Future Oncol. 2017 May;13(11):1035-1041. doi: 10.2217/fon-2016-0547.
INTRODUCTION: Breast cancer (BC) is the most common type of cancers with high rates of morbidity and mortality. By now numerous medical approaches are available for treatment of BC including chemotherapies, radiation and surgery. These are accompanied by several complications like partial effectiveness, fatal adverse effects and high cost. Numerous studies in recent years tried to find safe and effective alternatives. A promising candidate is coenzyme Q10 which is an antioxidant that can target the mechanisms of BC tumor progression. METHODS & RESULTS: In this systematic review via PubMed searching, sparse but promising findings were classified about the successful application of this compound as an adjunct in prevention and treatment of BC and its comorbidities with some contradicting data about its null effect. DISCUSSION & CONCLUSION: According to the results, further well-designed clinical studies with dose optimization are now required to stratify the role of this supplement in current BC regimens.
6Breast Molecular Profiling and Radiotherapy Considerations.PubMed
Omar Mahmoud, Bruce G Haffty
Adv Exp Med Biol. 2016;882:95-124. doi: 10.1007/978-3-319-22909-6_4.
The last decade has seen major changes in the management of breast cancer. Heterogeneity regarding histology, therapeutic response, dissemination patterns, and patient outcome is evident. Molecular profiling provides an accurate tool to predict treatment outcome compared with classical clinicopathologic features. The genomic profiling unveiled the heterogeneity of breast cancer and identified distinct biologic subtypes. These advanced techniques were integrated into the clinical management; predicting systemic therapy benefit and overall survival. Utilizing genotyping to guide locoregional management decisions needs further characterization. In this chapter we will review available data on molecular classification of breast cancer, their association with locoregional outcome, their radiobiological properties and radiotherapy considerations.
7Cryoablation for the Treatment of Breast Cancer: A Review of the Current Landscape and Future Possibilities.PubMed
Nicholas Pigg, Robert C Ward
Acad Radiol. 2023 Dec;30(12):3086-3100. doi: 10.1016/j.acra.2023.06.030. Epub 2023 Aug 16.
Breast cancer is one of the most common malignancies worldwide. Traditional treatment options for breast cancer include surgery, radiation therapy, and chemotherapy. However, cryoablation, a minimally invasive technique, has emerged as a promising alternative for the treatment of early-stage breast cancer. This article aims to provide an overview of cryoablation, focusing on incorporation into practice, patient selection, procedural technique, imaging follow-up, post-treatment radiopathological findings, and current and ongoing research in the field. The current evidence suggests that cryoablation offers a safe and effective treatment option for selected patients, providing comparable oncological outcomes to traditional treatments while minimizing invasiveness and preserving breast aesthetics.
8Managing anxiety and depression during treatment.PubMed
David Spiegel, Michelle B Riba
Breast J. 2015 Jan-Feb;21(1):97-103. doi: 10.1111/tbj.12355. Epub 2014 Nov 6.
Here, we review the prevalence and treatment of anxiety and depression among patients with breast cancer. Cancer-related symptoms include similarities to responses to traumatic stress. Well-developed screening devices for identifying and tracking psychiatric comorbidity are discussed. Basic principles of psychopharmacology, and individual and group psychotherapy are presented. Finally, effects of effective treatment of anxiety and depression on quality of life and overall survival are reviewed.
9NCCN: Breast cancer.PubMed
R W Carlson, S B Edge, R L Theriault, et al.
Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):54-61.
The 2001 NCCN Breast Cancer Guidelines reflect the results of 5 generations of NCCN Breast Cancer Guidelines. Evidence-based guidelines, such as the NNCN Breast Cancer Guidelines, are possible only because of the availability of high-level evidence at multiple decision points in treatment. The continued performance of high quality clinical trials is central to our ability to further improve the treatment of breast cancer. The panel believes that participation in high quality clinical trials is the preferred treatment at all points in breast cancer therapy.
10GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis.PubMed
Xue-Ying Hu, Xiang-Yang Huang, Jie Ma, et al.
Tumour Biol. 2016 Jan;37(1):151-62. doi: 10.1007/s13277-015-4401-3. Epub 2015 Nov 14.
Observational studies have reported controversial results on the association between GSTT1 and GSTM1 genotypes and treatment outcome of breast cancer. The purpose of this study is to evaluate the association between GSTT1 and GSTM1 and treatment outcome in breast cancer patients. Eligible studies were searched in PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure databases. A random-effect model or fixed-effect model was used to calculate the overall combined risk estimates. Twenty-one studies with a total of 4990 patients were included in this meta-analysis. The GSTM1 null genotype (odds ratio (OR) = 1.33, 95 % confidence interval (CI) 1.01-1.75, P = 0.046) and GSTT1/GSTM1 double null genotype (OR = 2.22, 95 % CI 1.02-4.84, P = 0.045) were significantly associated with an increased tumor response. A reduced overall survival (hazard ratio (HR) = 0.84, 95 % CI 0.72-0.98, P = 0.024) was observed in GSTM1 null genotype, especially in mixed descent (HR = 0.77, 95 % CI 0.61-0.96, P = 0.018) and large sample size (HR = 0.85, 95 % CI 0.72-0.99, P = 0.033). Evidence of publication bias was observed in GSTM1 genotype rather than in GSTT1 genotype. This meta-analysis suggests that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response. However, the GSTM1 null genotype might be significantly associated with a reduced overall survival. Future studies are warranted to confirm these findings.